CEP-9722
Based on 1 publication(s) in Google Scholar
CEP-9722, the proagent of CEP-8983, is a selective and orally active PARP-1 and PARP-2 inhibitor with IC50s of 20 nM and 6 nM, respectively. CEP-9722 has anticancer effects.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 916574-83-9
- Fòrmula: C24H26N4O3
- Peso molecular:418.49
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) CEP-9722
More
Actividad biológica
|
PARP-1 20 nM (IC50) |
PARP-2 6 nM (IC50) |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice bearing subcutaneous RT4 human urothelial carcinoma (UC) tumors[1]
-
Dosage:100 or 200 mg/kg/day
-
Administration:Oral gavage; once daily; for 5 days a week for 4 weeks
-
Result:Showed dose-dependent antitumor activity in RT4 xenografts.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 916574-83-9
-
Peso molecular 418.49
-
Fòrmula C24H26N4O3
-
SMILES
O=C(N1CN2CCN(C)CC2)C3=C4C5=C(OC)C=CC=C5NC4=C6C(CCC6)=C3C1=O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Pureza y Documentación
Referencias
[1]. Weiguo Jian, et al. Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage. Anticancer Drugs. 2014 Sep;25(8):878-86. [Content Brief]
[2]. Ruth Plummer, et al. Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors. Cancer Chemother Pharmacol. 2014 Aug;74(2):257-65. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
CEP-9722 Related Classifications
HY-105303 Related Classifications
Powered by Bioz